2月3日晚间，嘉事堂发布公告称，2月2日，公司股东光大实业、光大健康与同仁堂集团签署《股份转让 协议》，协议约定光大实业、光大健康分别将其持有的公司4118.08万股股份、4187.64万股股份转让给 同仁堂集团，转让价款总计为14.61亿元。 此次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市人民政府国有资产监 督管理委员会。公司股票自2月4日开市起复牌。 图片来源：公司公告 截至1月27日收盘，嘉事堂股价报16.4元/股，市值为47.8亿元。 尚需多项审批 公告显示，此次股份转让的每股价格为17.59元，转让总价款为14.61亿元。其中，光大健康转让股权占 公司总股本的14.36%；光大实业转让股权占公司总股本的14.12%。交易完成后，二者将不再持有公司 股份，同仁堂集团则以28.48%的持股比例成为控股股东。 公开资料显示，嘉事堂于1997年成立，2010年在深交所上市，2018年进入光大体系，是光大大健康业务 板块主要平台。嘉事堂主要业务涵盖二三级医院销售、社区医疗中心销售、物流配送、连锁零售，经营 范围包括药品、生物制品、医疗器械、中药饮片等。 业绩方面，公司2025年前三季 ...

Core Viewpoint - The control of Jiasitang (002462) is set to change hands to Tongrentang Group following a share transfer agreement, marking a significant shift in the company's ownership structure and strategic direction [2][3]. Group 1: Company Overview - Jiasitang is a leading pharmaceutical commercial enterprise in Beijing, serving over 300 secondary and tertiary hospitals with a coverage rate of 99% [3]. - The company specializes in the distribution of pharmaceuticals and medical devices, as well as healthcare products and services, aiming to become a top-tier comprehensive service provider in the domestic pharmaceutical circulation and healthcare sector [2]. - Jiasitang has faced declining profitability, with net profits decreasing from 3.54 billion yuan in 2021 to an estimated 1.61 billion yuan in 2024 [3]. Group 2: Strategic Implications of the Acquisition - The acquisition by Tongrentang Group is seen as a strategic move to enhance Jiasitang's capabilities in the pharmaceutical commercial sector, filling gaps in distribution and channel management [5]. - This transaction is expected to create a "production + commercial" closed loop, which is crucial for addressing centralized procurement and medical insurance cost control [5]. - The integration of Jiasitang under Tongrentang Group is part of a broader initiative by the Beijing State-owned Assets Supervision and Administration Commission to optimize state capital layout and strengthen the influence of state-owned capital in key public health sectors [5].

证券日报网讯2月3日，嘉事堂（002462）在互动平台回答投资者提问时表示，截至2026年1月30日，公 司股东共2万8千余户。 ...

嘉事堂表示，根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第6号 ——停复牌》等有关规定，经公司向深交所申请，公司股票自2月4日上午开市起复牌。 北京商报讯(记者丁宁)2月3日晚间，嘉事堂（002462）发布公告称，2月2日，公司股东光大实业、光大 健康与中国北京同仁堂（600085）(集团)有限责任公司(以下简称"同仁堂集团")签署了《股份转让协 议》，协议约定光大实业、光大健康分别将其持有的公司4118.08万股股份、4187.64万股股份转让给同 仁堂集团。本次交易完成后，公司控股股东将变更为同仁堂集团，实际控制人将变更为北京市人民政府 国有资产监督管理委员会。 ...

本次权益变动后，同仁堂集团将成为公司控股股东，北京市人民政府国有资产监督管理委员会（以下简 称"北京市国资委"）将成为公司实际控制人。公司股票（证券简称：嘉事堂，证券代码：002462）自 2026年2月4日（星期三）上午开市起复牌。 格隆汇2月3日丨嘉事堂(002462.SZ)公布，公司股东光大健康、光大实业与同仁堂集团签署了《股份转 让协议》，光大健康、光大实业将合计持有的公司83,057,236股股份（占公司股份总数的28.48%）转让 给同仁堂集团，转让价格为人民币17.59元/股，转让价款总计为人民币1,460,976,781.24元。其中光大健 康将其持有的公司41,876,431股股份（占公司总股本的14.36%）转让给同仁堂集团，转让价款为人民币 736,606,421.29元；光大实业将其持有的公司41,180,805股股份（占公司总股本的14.12%）转让给同仁堂 集团，转让价款为人民币724,370,359.95元。 ...

Market Performance - The pharmaceutical commercial sector increased by 1.72% compared to the previous trading day, with RunDa Medical leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Individual Stock Performance - RunDa Medical (603108) closed at 16.66, up 7.97% with a trading volume of 350,800 shares and a transaction value of 569 million yuan [1] - HeFu China (603122) closed at 18.36, up 4.73% with a trading volume of 212,800 shares and a transaction value of 385 million yuan [1] - Haiwang Biological (000078) closed at 3.76, up 4.44% with a trading volume of 1,319,000 shares and a transaction value of 487 million yuan [1] - Other notable stocks include: - Shangyu Pingmin (301017) at 17.21, up 4.11% - Yinghe Pharmaceutical (002788) at 16.18, up 3.59% - Guofa Co. (600538) at 7.32, up 3.24% [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 29.80 million yuan from institutional investors, while retail investors experienced a net inflow of 15.91 million yuan [2] - However, speculative funds recorded a net outflow of 45.71 million yuan [2] Detailed Capital Flow by Stock - RunDa Medical had a net inflow of 80.79 million yuan from institutional investors, but a net outflow of 47.58 million yuan from speculative funds [3] - HeFu China saw a net inflow of 31.37 million yuan from institutional investors, with a net outflow of 19.81 million yuan from speculative funds [3] - Haiwang Biological experienced a net inflow of 25.37 million yuan from institutional investors, with a net outflow of 10.47 million yuan from speculative funds [3]

【#壹快评#｜供货705万给院长回扣247万，#整治医药商业贿赂须行贿受贿一起查#】结合国家医保局通 报的四起案件，笔者认为，要根除医药商业贿赂顽疾，需多管齐下、持续发力。 其一，必须坚持"行贿受贿一起查"，破除"重打击受贿、轻惩治行贿"的惯性。行贿是贿赂犯罪的源头， 唯有对行贿行为予以严厉惩处，提高违法成本，才能有效震慑企图通过不正当手段获取利益的企业。其 二，要进一步完善医疗机构内部决策与监督机制，杜绝关键岗位人员"一言堂"，推进采购流程公开透 明，切断利益输送通道。其三，持续深化医药招采制度改革，扩大带量采购覆盖范围，让价格回归合理 区间，压缩贿赂生存空间。其四，强化医保基金监管与智能监控，对异常采购、使用行为及时预警核 查，提升发现与查处腐败的能力。 ...

Group 1 - The core viewpoint of the news is that Huaren Health has shown significant financial performance with a notable increase in revenue and net profit, alongside high financing and margin trading activity [1][2][3] Group 2 - As of February 2, Huaren Health's stock price increased by 0.43%, with a trading volume of 379 million yuan [1] - On February 2, the financing buy amount was 31.82 million yuan, while the financing repayment was 33.44 million yuan, resulting in a net financing outflow of 1.62 million yuan [1] - The total financing and margin trading balance for Huaren Health reached 186 million yuan, accounting for 5.89% of its market capitalization, indicating a high level of financing activity [1] Group 3 - As of September 30, the number of shareholders for Huaren Health was 20,100, a decrease of 22.86% from the previous period, while the average circulating shares per person increased by 29.64% to 7,422 shares [2] - For the period from January to September 2025, Huaren Health achieved an operating income of 3.892 billion yuan, representing a year-on-year growth of 19.06%, and a net profit attributable to shareholders of 157 million yuan, up 45.21% year-on-year [2] Group 4 - Since its A-share listing, Huaren Health has distributed a total of 80.02 million yuan in dividends [3] - As of September 30, 2025, Hong Kong Central Clearing Limited was the fifth largest circulating shareholder, holding 2.3203 million shares, an increase of 1.3357 million shares from the previous period [3]

Group 1 - The company has approved a share repurchase plan using its own and self-raised funds, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [1] - The repurchase period is set for up to 12 months from the board's approval date [1] - The company has repurchased 10.803 million shares, representing 2.72% of the total share capital, with a total expenditure of RMB 198.6382 million as of January 31, 2026 [2] Group 2 - The highest repurchase price recorded was RMB 19.07 per share, while the lowest was RMB 17.83 per share [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [3]

Core Viewpoint - Haiwang Biological (000078) expects a net profit loss attributable to shareholders of approximately 490 million to 600 million yuan for the fiscal year 2025, representing an increase in loss of 49.72% to 58.94% compared to the previous year's loss of 1.193 billion yuan [1] Group 1: Financial Performance - The main reason for the performance change is the optimization of business structure, which is expected to impact net profit loss by approximately 110 million to 150 million yuan [1] - The company anticipates goodwill impairment of about 120 million to 150 million yuan, with the scale of impairment significantly reduced compared to previous years [1] - Expected credit impairment losses are estimated to be between 150 million to 220 million yuan, indicating a generally good credit foundation, although some public medical institutions face long-term debt recovery issues [1]